The AR dependent cell cycle: Mechanisms and cancer relevance

Molecular and Cellular Endocrinology

Volumn 352, Issue 1-2, 2012, Pages 34-45

  Schiewer, Matthew J ^a,b   Augello, Michael A ^a,b   Knudsen, Karen E ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Androgen receptor; Cell cycle; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN A2; CYCLIN B1; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; CYCLIN E; CYCLIN E1; CYCLINE; G1 CYCLIN; PROTEIN P107; PROTEIN P130; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; FEEDBACK SYSTEM; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION;

CELL CYCLE; CELL PROLIFERATION; HUMANS; NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84857371687     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.06.033     Document Type: Review

References (187)

1. Aaltomaa S., Lipponen P., Eskelinen M., Ala-Opas M., Kosma V.M. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 1999, 39:8-15.
2. Agus D.B., Cordon-Cardo C., Fox W., Drobnjak M., Koff A., Golde D.W., et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst. 1999, 91:1869-1876.
3. Alt J.R., Gladden A.B., Diehl J.A. P21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J. Biol. Chem. 2002, 277:8517-8523.
4. Attard G., Reid A.H., A'Hern R., Parker C., Oommen N.B., Folkerd E., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 2009, 27:3742-3748.
5. Attard G., Reid A.H., Yap T.A., Raynaud F., Dowsett M., Settatree S., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 2008, 26:4563-4571.
6. Balk S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002, 60:132-138. discussion 138-9.
7. Balk S.P., Knudsen K.E. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal. 2008, 6:e001.
8. Baretton G.B., Klenk U., Diebold J., Schmeller N., Lohrs U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br. J. Cancer 1999, 80:546-555.
9. Ben-Izhak O., Lahav-Baratz S., Meretyk S., Ben-Eliezer S., Sabo E., Dirnfeld M., et al. Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J. Urol. 2003, 170:241-245.
10. Bienvenu F., Jirawatnotai S., Elias J.E., Meyer C.A., Mizeracka K., Marson A., et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature 2010, 463:374-378.
11. Bohrer L.R., Chen S., Hallstrom T.C., Huang H. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology 2010, 151:5136-5145.
12. Brooke G.N., Bevan C.L. The role of androgen receptor mutations in prostate cancer progression. Curr. Genomics 2009, 10:18-25.
13. Brooks J.D., Bova G.S., Isaacs W.B. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 1995, 26:35-39.
14. 2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol. Endocrinol. 2005, 19:607-620.
15. Burd C.J., Petre C.E., Morey L.M., Wang Y., Revelo M.P., Haiman C.A., et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc. Natl. Acad. Sci. USA 2006, 103:2190-2195.
16. Burkhart D.L., Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 2008, 8:671-682.
17. Cairns P., Polascik T.J., Eby Y., Tokino K., Califano J., Merlo A., et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 1995, 11:210-212.
18. Chakravarti A., DeSilvio M., Zhang M., Grignon D., Rosenthal S., Asbell S.O., et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J. Clin. Oncol. 2007, 25:3082-3089.
19. Chakravarti A., Heydon K., Wu C.L., Hammond E., Pollack A., Roach M., et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. J. Clin. Oncol. 2003, 21:3328-3334.
20. Chang B.L., Zheng S.L., Isaacs S.D., Wiley K.E., Turner A., Li G., et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res. 2004, 64:1997-1999.
21. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
22. Chen S., Xu Y., Yuan X., Bubley G.J., Balk S.P. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc. Natl. Acad. Sci. USA 2006, 103:15969-15974.
23. Chen W., Weghorst C.M., Sabourin C.L., Wang Y., Wang D., Bostwick D.G., et al. Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 1996, 17:2603-2607.
24. Chen Y., Sawyers C.L., Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 2008, 8:440-448.
25. Cheng L., Lloyd R.V., Weaver A.L., Pisansky T.M., Cheville J.C., Ramnani D.M., et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin. Cancer Res. 2000, 6:1896-1899.
26. Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M., et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999, 18:1571-1583.
27. Cheville J.C., Lloyd R.V., Sebo T.J., Cheng L., Erickson L., Bostwick D.G., et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod. Pathol. 1998, 11:324-328.
28. Chi S.G., deVere White R.W., Muenzer J.T., Gumerlock P.H. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin. Cancer Res. 1997, 3:1889-1897.
29. Chiu Y.T., Han H.Y., Leung S.C., Yuen H.F., Chau C.W., Guo Z., et al. CDC25A functions as a novel Ar corepressor in prostate cancer cells. J. Mol. Biol. 2009, 385:446-456.
30. Cho N.Y., Kim B.H., Choi M., Yoo E.J., Moon K.C., Cho Y.M., et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J. Pathol. 2007, 211:269-277.
31. Chodak G.W. Maximum androgen blockade: a clinical update. Rev. Urol. 2005, 7(Suppl. 5):S13-S17.
32. Chua S.S., Ma Z., Ngan E., Tsai S.Y. Cdc25B as a steroid receptor coactivator. Vitam. Horm. 2004, 68:231-256.
33. Claudio P.P., Zamparelli A., Garcia F.U., Claudio L., Ammirati G., Farina A., et al. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin. Cancer Res. 2002, 8:1808-1815.
34. Comstock C.E., Augello M.A., Benito R.P., Karch J., Tran T.H., Utama F.E., et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin. Cancer Res. 2009, 15:5338-5349.
35. Comstock, C.E., Augello, M.A., Schiewer, M.J., Karch, J., Burd, C.J., Ertel, A., et al., 2011. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J. Biol. Chem.
36. Comstock C.E., Revelo M.P., Buncher C.R., Knudsen K.E. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br. J. Cancer 2007, 96:970-979.
37. Cooney K.A., Wetzel J.C., Merajver S.D., Macoska J.A., Singleton T.P., Wojno K.J. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res. 1996, 56:1142-1145.
38. Cordon-Cardo C., Koff A., Drobnjak M., Capodieci P., Osman I., Millard S.S., et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. 1998, 90:1284-1291.
39. Cote R.J., Shi Y., Groshen S., Feng A.C., Cordon-Cardo C., Skinner D., et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst. 1998, 90:916-920.
40. Culig Z., Bartsch G. Androgen axis in prostate cancer. J. Cell Biochem. 2006, 99:373-381.
41. De Marzo A.M., Meeker A.K., Epstein J.I., Coffey D.S. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am. J. Pathol. 1998, 153:911-919.
42. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68:5469-5477.
43. Ding Z., Wu C.J., Chu G.C., Xiao Y., Ho D., Zhang J., et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
44. Doganavsargil B., Simsir A., Boyacioglu H., Cal C., Hekimgil M. A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int. 2006, 97:644-648.
45. Donovan M.J., Osman I., Khan F.M., Vengrenyuk Y., Capodieci P., Koscuiszka M., et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int. 2010, 105:462-467.
46. Dreher T., Zentgraf H., Abel U., Kappeler A., Michel M.S., Bleyl U., et al. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch. 2004, 444:509-517.
47. Drobnjak M., Melamed J., Taneja S., Melzer K., Wieczorek R., Levinson B., et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin. Cancer Res. 2003, 9:2613-2619.
48. Drobnjak M., Osman I., Scher H.I., Fazzari M., Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin. Cancer Res. 2000, 6:1891-1895.
49. Dunsmuir W.D., Gillett C.E., Meyer L.C., Young M.P., Corbishley C., Eeles R.A., et al. Molecular markers for predicting prostate cancer stage and survival. BJU Int. 2000, 86:869-878.
50. Erdamar S., Yang G., Harper J.W., Lu X., Kattan M.W., Thompson T.C., et al. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod. Pathol. 1999, 12:751-755.
51. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240:889-895.
52. Facher E.A., Becich M.J., Deka A., Law J.C. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer 1997, 79:2424-2429.
53. Faith D., Han S., Lee D.K., Friedl A., Hicks J.L., De Marzo A.M., et al. P16 Is upregulated in proliferative inflammatory atrophy of the prostate. Prostate 2005, 65:73-82.
54. Faus H., Haendler B. Post-translational modifications of steroid receptors. Biomed. Pharmacother. 2006, 60:520-528.
55. Fernandez P.L., Arce Y., Farre X., Martinez A., Nadal A., Rey M.J., et al. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J. Pathol. 1999, 187:563-566.
56. Freedland S.J., de Gregorio F., Sacoolidge J.C., Elshimali Y.I., Csathy G.S., Elashoff D.A., et al. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology 2003, 61:1187-1192.
57. Fu M., Rao M., Bouras T., Wang C., Wu K., Zhang X., et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J. Biol. Chem. 2005, 280:16934-16941.
58. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 2002, 20:3001-3015.
59. Gnanapragasam V.J., Robson C.N., Leung H.Y., Neal D.E. Androgen receptor signalling in the prostate. BJU Int. 2000, 86:1001-1013.
60. Gordon V., Bhadel S., Wunderlich W., Zhang J., Ficarro S.B., Mollah S.A., et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol. Endocrinol. 2010, 24:2267-2280.
61. Gu K., Mes-Masson A.M., Gauthier J., Saad F. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol. Carcinog. 1998, 21:164-170.
62. Guo Y., Sklar G.N., Borkowski A., Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res. 1997, 3:2269-2274.
63. Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009, 69:2305-2313.
64. Halvorsen O.J., Haukaas S.A., Akslen L.A. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin. Cancer Res. 2003, 9:1474-1479.
65. Halvorsen O.J., Hostmark J., Haukaas S., Hoisaeter P.A., Akslen L.A. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 2000, 88:416-424.
66. He B., Kemppainen J.A., Voegel J.J., Gronemeyer H., Wilson E.M. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J. Biol. Chem. 1999, 274:37219-37225.
67. Heemers H.V., Regan K.M., Schmidt L.J., Anderson S.K., Ballman K.V., Tindall D.J. Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol. 2009, 23:572-583.
68. Heidenreich B., Heidenreich A., Sesterhenn A., Srivastava S., Moul J.W., Sesterhenn I.A. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur. Urol. 2000, 38:475-482.
69. Heinlein C.A., Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 2002, 23:175-200.
70. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25:276-308.
71. Henrique R., Costa V.L., Cerveira N., Carvalho A.L., Hoque M.O., Ribeiro F.R., et al. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J. Mol. Med. 2006, 84:911-918.
72. Henshall S.M., Quinn D.I., Lee C.S., Head D.R., Golovsky D., Brenner P.C., et al. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin. Cancer Res. 2001, 7:544-550.
73. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69:16-22.
74. Huang S.P., Yu C.C., Liu C.C., Wu T.T., Huang C.H., Wu M.T. CDKN1B V109G polymorphism frequency and prostate cancer risk in Taiwan. Urol. Int. 2008, 81:36-40.
75. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972, 22:232-240.
76. Iemelynova A.A., Grygorenko V.M., Cheremuha S.V., Romanenko A.M. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation. Exp. Oncol. 2009, 31:246-249.
77. Ittmann M.M., Wieczorek R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum. Pathol. 1996, 27:28-34.
78. Jarrard D.F., Bova G.S., Ewing C.M., Pin S.S., Nguyen S.H., Baylin S.B., et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 1997, 19:90-96.
79. Jarrard D.F., Modder J., Fadden P., Fu V., Sebree L., Heisey D., et al. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett. 2002, 185:191-199.
80. Jeronimo C., Henrique R., Hoque M.O., Mambo E., Ribeiro F.R., Varzim G., et al. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 2004, 10:8472-8478.
81. Jin F., Fondell J.D. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression. Nucleic Acids Res. 2009, 37:4826-4838.
82. Kallakury B.V., Sheehan C.E., Ambros R.A., Fisher H.A., Kaufman R.P., Ross J.S. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 1997, 80:753-763.
83. Kallakury B.V., Sheehan C.E., Rhee S.J., Fisher H.A., Kaufman R.P., Rifkin M.D., et al. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 1999, 85:1569-1576.
84. Kaltz-Wittmer C., Klenk U., Glaessgen A., Aust D.E., Diebold J., Lohrs U., et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab. Invest. 2000, 80:1455-1464.
85. Kibel A.S., Christopher M., Faith D.A., Bova G.S., Goodfellow P.J., Isaacs W.B. Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate 2001, 48:248-253.
86. Kibel A.S., Faith D.A., Bova G.S., Isaacs W.B. Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J. Urol. 2000, 164:192-196.
87. Kibel A.S., Suarez B.K., Belani J., Oh J., Webster R., Brophy-Ebbers M., et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003, 63:2033-2036.
88. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000, 88:3009-3014.
89. Klotz L. Combined androgen blockade: an update. Urol. Clin. North Am. 2006, 33:161-166. v-vi.
90. Knudsen E.S., Knudsen K.E. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp. Biol. Med. (Maywood) 2006, 231:1271-1281.
91. Knudsen E.S., Knudsen K.E. Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 2008, 8:714-724.
92. Knudsen K.E. The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div. 2006, 1:15.
93. Knudsen K.E., Arden K.C., Cavenee W.K. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J. Biol. Chem. 1998, 273:20213-20222.
94. Knudsen K.E., Cavenee W.K., Arden K.C. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res. 1999, 59:2297-2301.
95. Knudsen K.E., Penning T.M. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab. 2010, 21:315-324.
96. Knudsen K.E., Scher H.I. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin. Cancer Res. 2009, 15:4792-4798.
97. Kobayashi T., Nakamura E., Shimizu Y., Terada N., Maeno A., Kobori G., et al. Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells. Biochem. Biophys. Res. Commun. 2009, 387:196-201.
98. Komiya A., Suzuki H., Aida S., Yatani R., Shimazaki J. Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn. J. Cancer Res. 1995, 86:622-625.
99. Konishi N., Nakamura M., Kishi M., Nishimine M., Ishida E., Shimada K. DNA hypermethylation status of multiple genes in prostate adenocarcinomas. Jpn. J. Cancer Res. 2002, 93:767-773.
100. Kuczyk M., Machtens S., Hradil K., Schubach J., Christian W., Knuchel R., et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br. J. Cancer 1999, 81:1052-1058.
101. Kuczyk M.A., Bokemeyer C., Hartmann J., Schubach J., Walter C., Machtens S., et al. Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol. Rep. 2001, 8:1401-1407.
102. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11:847-862.
103. Labrie F., Belanger A., Simard J., Luu-The V., Labrie C. " Intracrinology" Autonomy and freedom of peripheral tissues. Ann. Endocrinol. (Paris) 1995, 56:23-29.
104. Labrie F., Luu-The V., Lin S.X., Simard J., Labrie C., El-Alfy M., et al. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 2000, 25:1-16.
105. Lacombe L., Maillette A., Meyer F., Veilleux C., Moore L., Fradet Y. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int. J. Cancer 2001, 95:135-139.
106. Lee C.T., Capodieci P., Osman I., Fazzari M., Ferrara J., Scher H.I., et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin. Cancer Res. 1999, 5:977-983.
107. Lee D.K., Duan H.O., Chang C. From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator. J. Biol. Chem. 2000, 275:9308-9313.
108. Lee Y.M., Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 2006, 5:2110-2114.
109. Li C., Larsson C., Futreal A., Lancaster J., Phelan C., Aspenblad U., et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998, 16:481-487.
110. Li J., Lin Q., Wang W., Wade P., Wong J. Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev. 2002, 16:687-692.
111. Li R., Wheeler T.M., Dai H., Sayeeduddin M., Scardino P.T., Frolov A., et al. Biological correlates of p27 compartmental expression in prostate cancer. J. Urol. 2006, 175:528-532.
112. Lim J.T., Mansukhani M., Weinstein I.B. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc. Natl. Acad. Sci. USA 2005, 102:5156-5161.
113. Lin H.M., Zhao L., Cheng S.Y. Cyclin D1 Is a Ligand-independent Co-repressor for Thyroid Hormone Receptors. J. Biol. Chem. 2002, 277:28733-28741.
114. Linja M.J., Porkka K.P., Kang Z., Savinainen K.J., Janne O.A., Tammela T.L., et al. Expression of androgen receptor coregulators in prostate cancer. Clin. Cancer Res. 2004, 10:1032-1040.
115. Litvinov I.V., Vander Griend D.J., Antony L., Dalrymple S., De Marzo A.M., Drake C.G., et al. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc. Natl. Acad. Sci. USA 2006, 103:15085-15090.
116. Locke J.A., Guns E.S., Lubik A.A., Adomat H.H., Hendy S.C., Wood C.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008, 68:6407-6415.
117. Lu J., Danielsen M. Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein. J. Biol. Chem. 1998, 273:31528-31533.
118. Lu L., Schulz H., Wolf D.A. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol. 2002, 3:22.
119. Lu S., Liu M., Epner D.E., Tsai S.Y., Tsai M.J. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol. Endocrinol. 1999, 13:376-384.
120. Ma Z.Q., Liu Z., Ngan E.S., Tsai S.Y. Cdc25B functions as a novel coactivator for the steroid receptors. Mol. Cell. Biol. 2001, 21:8056-8067.
121. Mack P.C., Chi S.G., Meyers F.J., Stewart S.L., deVere White R.W., Gumerlock P.H. Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate 1998, 34:145-151.
122. Maddison L.A., Huss W.J., Barrios R.M., Greenberg N.M. Differential expression of cell cycle regulatory molecules and evidence for a " cyclin switch" during progression of prostate cancer. Prostate 2004, 58:335-344.
123. Mallik I., Davila M., Tapia T., Schanen B., Chakrabarti R. Androgen regulates Cdc6 transcription through interactions between androgen receptor and E2F transcription factor in prostate cancer cells. Biochim. Biophys. Acta 2008, 1783:1737-1744.
124. Malumbres M., Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 2007, 17:60-65.
125. Marivoet S., Van Dijck P., Verhoeven G., Heyns W. Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments. Mol. Cell Endocrinol. 1992, 88:165-174.
126. Maruyama R., Toyooka S., Toyooka K.O., Virmani A.K., Zochbauer-Muller S., Farinas A.J., et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 2002, 8:514-519.
127. Mashal R.D., Lester S., Corless C., Richie J.P., Chandra R., Propert K.J., et al. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 1996, 56:4159-4163.
128. Matsushima H., Sasaki T., Goto T., Hosaka Y., Homma Y., Kitamura T., et al. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum. Pathol. 1998, 29:778-783.
129. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008, 68:4447-4454.
130. Nash A.F., Melezinek I. The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocr. Relat. Cancer 2000, 7:37-51.
131. Ngan E.S., Hashimoto Y., Ma Z.Q., Tsai M.J., Tsai S.Y. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003, 22:734-739.
132. Nguyen, P.L., Lin, D.I., Lei, J., Fiorentino, M., Mueller, E., Weinstein, M.H., et al., 2009. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol. Oncol.
133. Nguyen T.T., Nguyen C.T., Gonzales F.A., Nichols P.W., Yu M.C., Jones P.A. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers. Prostate 2000, 43:233-242.
134. Nikoleishvili D., Pertia A., Trsintsadze O., Gogokhia N., Managadze L., Chkhotua A. Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells. Int. Urol. Nephrol. 2008, 40:953-959.
135. Olshavsky N.A., Comstock C.E., Schiewer M.J., Augello M.A., Hyslop T., Sette C., et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res. 2010, 70:3975-3984.
136. Olshavsky N.A., Groh E.M., Comstock C.E., Morey L.M., Wang Y., Revelo M.P., et al. Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene 2008, 27:3111-3121.
137. Omar E.A., Behlouli H., Chevalier S., Aprikian A.G. Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 2001, 49:191-199.
138. Ozen M., Ittmann M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin. Cancer Res. 2005, 11:4701-4706.
139. Padar A., Sathyanarayana U.G., Suzuki M., Maruyama R., Hsieh J.T., Frenkel E.P., et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res. 2003, 9:4730-4734.
140. Pal S.K., Sartor O. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 2011, 68:103-105.
141. Peng Y., Chen F., Melamed J., Chiriboga L., Wei J., Kong X., et al. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc. Natl. Acad. Sci. USA 2008, 105:5236-5241.
142. Penning T.M., Steckelbroeck S., Bauman D.R., Miller M.W., Jin Y., Peehl D.M., et al. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol. Cell Endocrinol. 2006, 248:182-191.
143. Perinchery G., Bukurov N., Nakajima K., Chang J., Li L.C., Dahiya R. High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer. Int. J. Cancer 1999, 83:610-614.
144. Petre C.E., Wetherill Y.B., Danielsen M., Knudsen K.E. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J. Biol. Chem. 2002, 277:2207-2215.
145. Petre-Draviam C.E., Cook S.L., Burd C.J., Marshall T.W., Wetherill Y.B., Knudsen K.E. Specificity of cyclin D1 for androgen receptor regulation. Cancer Res. 2003, 63:4903-4913.
146. Petre-Draviam C.E., Williams E.B., Burd C.J., Gladden A., Moghadam H., Meller J., et al. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 2005, 24:431-444.
147. Reutens A.T., Fu M., Wang C., Albanese C., McPhaul M.J., Sun Z., et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol. Endocrinol. 2001, 15:797-811.
148. Ribal M.J., Fernandez P.L., Lopez-Guillermo A., Farre X., Santos Y., Gibanel R., et al. Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer. Anticancer Res. 2003, 23:5101-5106.
149. Riegman P.H., Vlietstra R.J., van der Korput J.A., Brinkmann A.O., Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 1991, 5:1921-1930.
150. Roach M., Waldman F., Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009, 115:3112-3120.
151. Romics I., Banfi G., Szekely E., Krenacs T., Szende B. Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer. Pathol. Oncol. Res. 2008, 14:307-311.
152. Rosenbaum E., Hoque M.O., Cohen Y., Zahurak M., Eisenberger M.A., Epstein J.I., et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res. 2005, 11:8321-8325.
153. Ryan C.J., Smith A., Lal P., Satagopan J., Reuter V., Scardino P., et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology 2006, 68:834-839.
154. Sarkar F.H., Li Y., Sakr W.A., Grignon D.J., Madan S.S., Wood D.P., et al. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 1999, 40:256-260.
155. Schiewer M.J., Morey L.M., Burd C.J., Liu Y., Merry D.E., Ho S.M., et al. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene 2009, 28:1016-1027.
156. Shand R.L., Gelmann E.P. Molecular biology of prostate-cancer pathogenesis. Curr. Opin. Urol. 2006, 16:123-131.
157. Shang Y., Myers M., Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 2002, 9:601-610.
158. Sharma A., Comstock C.E., Knudsen E.S., Cao K.H., Hess-Wilson J.K., Morey L.M., et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 2007, 67:6192-6203.
159. Sharma A., Yeow W.S., Ertel A., Coleman I., Clegg N., Thangavel C., et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. 2010, 120:4478-4492.
160. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
161. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004, 18:2699-2711.
162. Shiraishi T., Watanabe M., Muneyuki T., Nakayama T., Morita J., Ito H., et al. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol. Int. 1998, 61:90-94.
163. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66:2815-2825.
164. Steinkamp M.P., O'Mahony O.A., Brogley M., Rehman H., Lapensee E.W., Dhanasekaran S., et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009, 69:4434-4442.
165. Sun H., Wang Y., Chinnam M., Zhang X., Hayward S.W., Foster B.A., et al. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. Proc. Natl. Acad. Sci. USA 2011, 108:704-709.
166. Tamimi Y., Bringuier P.P., Smit F., van Bokhoven A., Debruyne F.M., Schalken J.A. P16 mutations/deletions are not frequent events in prostate cancer. Br. J. Cancer 1996, 74:120-122.
167. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
168. Thomas G.V., Schrage M.I., Rosenfelt L., Kim J.H., Salur G., deKernion J.B., et al. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J. Urol. 2000, 164:1987-1991.
169. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
170. Trapman J., Brinkmann A.O. The androgen receptor in prostate cancer. Pathol. Res. Pract. 1996, 192:752-760.
171. Tsihlias J., Kapusta L.R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998, 58:542-548.
172. Uhlen M., Oksvold P., Fagerberg L., Lundberg E., Jonasson K., Forsberg M., et al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 2010, 28:1248-1250.
173. Vis A.N., Noordzij M.A., Fitoz K., Wildhagen M.F., Schroder F.H., van der Kwast T.H. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J. Urol. 2000, 164:2156-2161.
174. Vis A.N., van Rhijn B.W., Noordzij M.A., Schroder F.H., van der Kwast T.H. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J. Pathol. 2002, 197:148-154.
175. Wang Q., Li W., Zhang Y., Yuan X., Xu K., Yu J., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138:245-256.
176. Wolters T., Vissers K.J., Bangma C.H., Schroder F.H., van Leenders G.J. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int. 2010, 106:280-286.
177. 2-terminal and steroid-binding domains. J. Biol. Chem. 1993, 268:19004-19012.
178. Wu T.T., Wang J.S., Jiaan B.P., Yu C.C., Tsai J.Y., Lin J.T., et al. Role of p21(WAF1) and p27(KIP1) in predicting biochemical recurrence for organ-confined prostate adenocarcinoma. J. Chin. Med. Assoc. 2007, 70:11-15.
179. Xu Y., Chen S.Y., Ross K.N., Balk S.P. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 2006, 66:7783-7792.
180. Yamamoto A., Hashimoto Y., Kohri K., Ogata E., Kato S., Ikeda K., et al. Cyclin E as a coactivator of the androgen receptor. J. Cell Biol. 2000, 150:873-880.
181. Yang G., Ayala G., De Marzo A., Tian W., Frolov A., Wheeler T.M., et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. 2002, 8:3419-3426.
182. Yang R.M., Naitoh J., Murphy M., Wang H.J., Phillipson J., deKernion J.B., et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 1998, 159:941-945.
183. Yeh S., Miyamoto H., Nishimura K., Kang H., Ludlow J., Hsiao P., et al. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem. Biophys. Res. Commun. 1998, 248:361-367.
184. Yuan X., Balk S.P. Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol. 2009, 27:36-41.
185. Zeng L., Rowland R.G., Lele S.M., Kyprianou N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum. Pathol. 2004, 35:290-297.
186. Zhang Z., Rosen D.G., Yao J.L., Huang J., Liu J. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod. Pathol. 2006, 19:1339-1343.
187. Zong H., Chi Y., Wang Y., Yang Y., Zhang L., Chen H., et al. Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Mol. Cell. Biol. 2007, 27:7125-7142.